GSK Reports 7% Sales Increase in Fiscal Year 2025 Driven by Oncology and HIV Drug Growth

GSK reported a 7% increase in sales for the fiscal year 2025, driven primarily by growth in its oncology and HIV drug portfolios. The pharmaceutical company attributed this rise to strong performance from key products in these areas, as well as advancements in its research and development (R&D) strategy. This comes as GSK prepares to address the challenges posed by upcoming patent expirations within its existing portfolio.

The company has focused on accelerating its R&D efforts and introducing new treatments to sustain growth amid potential revenue losses from expiring patents. GSK’s leadership expressed confidence that these measures, along with recent product launches, will help mitigate the impact of such expirations. The financial results reflect the company’s ongoing efforts to strengthen its position in critical therapeutic areas while navigating industry challenges.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 4, 2026

Author

GOAI